|
|
||||||||
1 Regulatory Peptide Center, Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, Nebraska 68178; and 2 Indiana University School of Medicine, South Bend Center for Medical Education, University of Notre Dame, Notre Dame, Indiana 46556
| |
ABSTRACT |
|---|
|
|
|---|
Endothelin (ET) from a nontetrapod
species has never been characterized, either structurally or
biologically. A single molecular form of trout ET with 21-amino-acid
residues was isolated in pure form from an extract of the kidney of the
steelhead trout, Oncorhynchus mykiss
and its primary structure established as
Cys-Ser-Cys-Ala-Thr-Phe-Leu-Asp-Lys-Glu10-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile20-Trp.
This amino acid sequence shows only three substitutions (Ala4
Ser,
Thr5
Ser, and
Phe6
Trp) compared with
human ET-2, demonstrating that the structure of the peptide has been
well conserved during evolution and that the pathway of
posttranslational processing of preproendothelin in the trout is
probably similar to that in mammals. Synthetic trout ET produced
concentration-dependent constrictions of isolated rings of vascular
tissue from trout efferent branchial artery (EBA;
pD2 = 7.90 ± 0.06, n = 5), caeliacomesenteric artery
(pD2 = 8.03 ± 0.04, n = 4), anterior cardinal vein (ACV;
pD2 = 8.57 ± 0.25, n = 4), and rat abdominal aorta (AO;
pD2 = 8.86 ± 0.08, n = 7). Trout and rat vessels were
more sensitive to mammalian ET-1 than to trout ET
(pD2 for human ET-1 in: EBA = 9.12 ± 0.14; ACV = 9.90 ± 0.15; AO = 8.86 ± 0.08), but there was
no significant difference in the maximum tension produced by either
peptide in these vessels.
teleost; rat; vasoconstrictor; peptide synthesis
| |
INTRODUCTION |
|---|
|
|
|---|
DESPITE THE IMPORTANT and diverse roles of the endothelin (ET) family of peptides in the regulation of mammalian physiological processes and in the pathophysiology of human diseases (23), our understanding of the structural and biological properties of ET-related peptides from nonmammalian species is very limited. Immunohistochemical studies using antisera to porcine ET-1 have provided evidence for the presence of peptides with ET-like immunoreactivity in range of invertebrate and vertebrate species. For example, ET-containing neurons have been detected in several species of mollusk and insect and in the protochordate Ciona intestinalis (10). ET-containing endocrine-like cells have been identified in the adenohypophysis of the lamprey, Lampetra japonica, in the kidney, gill, and caudal neurosecretory and neurohypophysial systems of the teleost, Oryzial latipes (10), and in the gill filament and lamellar epithelium of several species of teleost (34), holostean (5), and elasmobranch (34) fish. With the use of an ET-3-specific antiserum, ET-3-like immunoreactivity was detected in gonadotrophs throughout the pars distalis of the pituitary of the female bullfrog, Rana catesbeiana (28). Prior to the present study, the only nonmammalian ET-like peptides to be characterized structurally were the sarafotoxins, a family of five isoforms, isolated from the venom of the snake, Atractaspis engaddensis (30). The sarafotoxins, like the endothelins, comprise 21-amino-acid residues, possess the same pattern of disulfide linkages, and exhibit strong vasoconstrictor activity (3, 12). However, structural similarity between genes encoding the biosynthetic precursors of the sarafotoxins (29) and the ETs (8) is minimal outside the bioactive region so that the evolutionary relationships between the two families are unclear.
Evidence that tissues of nonmammalian vertebrates express ET receptors has also been obtained. With the use of 125I-labeled sarafotoxin-b as tracer, specific binding sites for ET-related peptides were identified in membrane preparations from the heart and brain of the Torpedo and tilapia (35). Similar studies using 125I-labeled porcine ET-1 revealed the presence of specific binding sites in gill, heart, liver, kidney, and intestine of the trout (17). High-affinity ET-1 binding sites have also been identified in liver (20), heart (14), and oocytes (15) of the toad Xenopus laevis. Two Xenopus ET-receptor subtypes have been cloned and characterized: ETAX from heart (14) and ETC from dermal melanophores (9), and a novel ET-receptor subtype (termed ETB2) in quail has also been cloned and characterized (16).
Functional studies have shown that the vasculatures of fish and amphibia are extremely sensitive to ET, thereby suggesting that the cardiovascular role of this peptide has been highly conserved during the course of vertebrate evolution. For example, human ET-1 potently (EC50 <10 nM) constricts isolated vascular rings prepared from arteries and veins of the frog, Rana pipiens (22), toad, Bufo viridis (3), catfish, Amiurus melas (22), trout, Oncorhynchus mykiss (21), and spiny dogfish, Squalus acanthias (4). Bolus injection of low doses of porcine ET-1 (500 ng/kg body weight) into unanesthetized trout produced transient depressor and sustained pressor responses, as in mammals, with higher doses (1,500 ng/kg body weight) producing a triphasic (pressor-depressor-pressor) response (21). In isolated heart preparations of the elasmobranch, Torpedo ocellata and the teleost, Oreochromis niloticus (tilapia), concentrations of ET-1 and sarafotoxin-b as low as 50 ng/ml induced positive inotropic effects, reduction of the contraction rate, and arrhythmia (35).
In most mammalian tissues, ET is secreted by the constitutive pathway (19) with the result that steady-state concentrations of the peptide in tissues are very low. This poses a challenge to the peptide chemist to obtain sufficient pure material to permit structural characterization, but recent advances in the instrumentation of microsequence analysis allow amino acid sequence determination of very low picomole amounts of peptide. This study extends our understanding of the evolution of the ET family of peptides by describing the purification, structural characterization, and chemical synthesis in the biologically active form of ET from a teleost fish, the steelhead trout (Oncorhynchus mykiss).
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Radioimmunoassay. ET-like
immunoreactivity (ET-LI) was measured using an antiserum raised against
human ET-1 that shows 60% cross-reactivity with human ET-2, 70%
cross-reactivity with human ET-3, but only 0.1% reactivity with
"big" human ET-1(1
38) (31). 125I-labeled human ET-1 (Amersham
Life Science, Arlington Heights, IL; specific activity 74 TBq/mM) was
used as tracer. The minimum detectable concentration using human ET-1
as standard was ~1 fmol/tube.
Tissue extraction. In a preliminary experiment, whole brain, heart, intestine, gill, liver, kidney, and caeliacomesenteric artery (CMA) from three specimens of adult rainbow trout were pooled and extracted with 10 volumes of ice-cold 3:1 ethanol/0.7 M HCl (by vol) using a Polytron homogenizer. Pooled plasma (10 ml) from three specimens was extracted by the same procedure. After centrifugation (1,600 g, 30 min, 4°C), an aliquot of each extract was freeze-dried and reconstituted in radioimmunoassay buffer (0.1 M sodium phosphate, pH 7.4, containing 0.4% bovine serum albumin) to give a final concentration equivalent to ~100 mg tissue/ml.
For the preparative study, frozen kidney (1,006 g) from steelhead trout (migratory Skamania strain) was homogenized with 10 volumes of ice-cold 3:1 ethanol/0.7 M HCl (by vol) using a Waring blender. The homogenate was stirred for 3 h at 0°C, centrifuged (1,600 g, 30 min, 4°C), and ethanol was removed from the supernatant under reduced pressure. Peptide material was isolated from the extract using Sep-Pak C18 cartridges (Waters Associates, Milford, MA) as previously described (33). Bound material was eluted with a mixture of acetonitrile, water, and trifluoroacetic acid (70.0:29.9:0.1, by vol) and freeze-dried.
Purification. The tissue extract, after partial purification on Sep-Pak cartridges, was redissolved in 1% (by vol) acetic acid/water (8 ml) and chromatographed on a (100 × 2.5 cm) column of Sephadex G-25 (Pharmacia Biotech, Uppsala, Sweden) equilibrated with 1 M acetic acid. The column was eluted at a flow rate of 48 ml/h, and fractions (8 ml) were collected. Absorbance was measured at 280 nm. The concentration of ET-LI in the fractions was determined by radioimmunoassay at a dilution of 1:100. Fractions containing ET-LI were pooled and pumped onto a 25 × 1-cm Vydac 218TP510 (C18) reverse-phase HPLC column (Separations Group, Hesperia, CA) equilibrated with 0.1% (by vol) trifluoroacetic acid/water at a flow rate of 2 ml/min. The concentration of acetonitrile in the eluting solvent was raised to 21% over 10 min and to 49% over 60 min using linear gradients. Absorbance was monitored at 214 and 280 nm, and fractions (1 min) were collected. The fraction containing ET-LI was rechromatographed on a 25 × 1-cm Vydac 214TP510 (C4) column equilibrated with a mixture of acetonitrile, water, and trifluoroacetic acid (21.0:78.9:0.1; by vol) at a flow rate of 2 ml/min. The concentration of acetonitrile in the eluting solvent was raised to 42% over 40 min using a linear gradient. Trout ET was purified to near homogeneity by successive chromatographies on 250 × 4.6-mm Vydac 214TP54 (C4), Vydac 219TP54 (phenyl), and Vydac 218TP54 (C18) columns at a flow rate of 1.5 ml/min. The concentration of acetonitrile in the eluting solvent was raised 21 to 42% over 40 min using a linear gradient.
Structural analysis. The primary structure of the peptide was determined by automated Edman degradation using a Perkin-Elmer Procise 491A sequenator. Mass spectrometry of the peptide was performed on a Voyager RP MALDI-TOF instrument (Perspective Biosystems, Framingham, MA) equipped with a nitrogen laser (337 nm). The instrument was operated in linear mode with delayed extraction, and the accelerating voltage in the ion source was 25 kV. Approximately 10 pmol of sample was used, and the accuracy of the mass determinations was at least 0.05%.
Peptide synthesis. Trout ET was synthesized by solid-phase methodology on a 0.025 mM scale on an Applied Biosystems model 432A peptide synthesizer using a 4-(2',4'-dimethoxy-phenyl-Fmoc-aminomethyl)phenoxyacetamidoethyl resin (Perkin Elmer, Foster City, CA). Fmoc amino acid derivatives were activated with O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (1 equivalent), 1-hydroxy-benzotriazole hydrate (1 equivalent), and diisopropylethylamine (2 equivalents). Deprotection of the NH2 terminus by piperidine was monitored by online measurement of the conductance of the carbamate salt of the Fmoc group, and optimum coupling times were determined by the instrument in response to the deprotection times. The peptide was cleaved from the resin with a mixture of trifluoroacetic acid, water, thioanisole, and 1,2-ethanedithiol (90.0:2.50:2.50:5.0) at 25°C for 3 h. The unpurified peptide was dissolved in 0.1 M ammonium acetate, pH 8.0 (500 ml) and subjected to air oxidation at room temperature for 24 h. The crude cyclized peptide was chromatographed on a 25 × 1-cm Vydac 218TP510 C18 equilibrated with 0.1% (by vol) trifluoroacetic acid and water at a flow rate of 2 ml/min. The concentration of acetonitrile in the eluting solvent was raised to 21% over 10 min followed by a raise to 49% over 60 min using linear gradients. The major peaks in the chromatogram were collected by hand, and aliquots were tested for ability to constrict vascular rings of the trout epibranchial artery as described in the next section.
Isolated trout vessels. The CMA, the
efferent branchial artery (EBA) from the third gill arch, and the
anterior cardinal vein (ACV) were removed from anesthetized (0.4 g/l
benzocaine) rainbow trout (kamloops
strain; 0.3-0.6 kg) and placed in HEPES-buffered saline (HBS) at
4°C. With the use of a procedure previously described (21), loose
connective tissue and blood were removed from the adventitia and 3- to
4-mm wide rings were cut from the center of each vessel. The vascular
rings were suspended from 280-µm diameter steel hooks in individual
20-ml water-jacketed (12 ± 1°C) chambers containing HBS
continuously gassed with room air. Tension was measured with Grass
FT03C force-displacement transducers and recorded on a Gould series
8000S polygraph. The rings were equilibrated at a resting tension of
500 mg (200 mg for ACV) for 1 h, contracted with either
10
5 M epinephrine (CMA and
EBA) or 10
5 M acetylcholine
(ACV), washed three times with HBS, and reequilibrated at a tension of
500 mg for 30 min. The effect of trout ET-1
(10
11
3 × 10
7 M) on the tension of
the rings was measured by cumulative addition of the peptides.
Comparisons between vessels were made with ANOVA (one way with
Bonferroni adjustment) with the significance level set at
P < 0.05. All values are means ± SE.
Isolated rat vessels. White male Wistar rats (300-500 g) were anesthetized with an intraperitoneal injection of nembutal (2 mg/kg body weight), and the abdominal aorta was exposed by a midline incision and removed. The vessels were cleared of blood, and 3-mm long aortic rings were placed in Krebs-Henseleit solution (37°C, pH 7.4) in the smooth muscle chambers described in Isolated trout vessels and gassed with 95% O2-5% CO2. Approximately 300 mg of resting tension was applied for 1 h before; the vessels were then contracted with 40 mM KCl, rinsed, and baseline tension was reestablished for an additional 1 h prior to experimentation. Other procedures were identical to those used on the trout vessels.
Solutions. HBS consisted of (in mM): 145 NaCl, 3 KCl, 2 CaCl2, 0.57 MgSO4, 5 glucose, 7 HEPES sodium salt, and 3 HEPES (acid form); pH adjusted to 7.8. Krebs-Hensleit solution consisted of (in mM): 15 NaCl, 25 NaHCO3, 1.38 NaH2PO4, 2.51 KCl, 2.46 MgSO4, 1.91 CaCl2, and 5.56 glucose; pH 7.4.
| |
RESULTS |
|---|
|
|
|---|
ET-LI in extracts of trout tissue. Extracts of trout whole brain, heart, intestine, gill, liver, and CMA, at a concentration of ~100 mg tissue/ml, and the extract of trout plasma did not contain detectable ET-LI. Only the extract of trout kidney contained material that inhibited the binding of 125I-labeled human ET-1 to the antiserum to human ET-1, but the immunoreactivity in serial dilutions of the extract did not diminish in parallel with the human ET-1 standard curve.
Peptide purification. The extract of
trout kidney, after partial purification on Sep-Pak cartridges, was
subjected to gel permeation chromatography on a Sephadex G-25 column.
ET-LI was eluted as a broad peak with a distribution coefficient
(KAV) between 0.55 and 0.75. These fractions were pooled and chromatographed on a
semipreparative Vydac C18 column,
and the elution profile is shown in Fig. 1.
ET-LI was associated with the single fraction denoted by the bar. Trout
ET was purified to near homogeneity, as assessed by peak symmetry, by
successive chromatographies on a semipreparative Vydac
C4 column (Fig.
2A), an
analytical Vydac C4 column (Fig.
2B), an analytical Vydac phenyl
column (Fig. 2C), and an analytical
Vydac C18 column (Fig.
2D). The final yield of pure peptide
was ~40 pmol, estimated from its absorbance at 214 nm.
|
|
Structural characterization. The primary structure of trout ET was determined by Edman degradation using an automated microsequence analyzer. The amino acid sequence of the peptide was established as Xaa-Ser-Xaa-Ala-Thr-Phe-Leu-Asp-Lys-Glu-Xaa-Val-Tyr-Phe-Xaa-His-Leu-Asp-Ile-Ile-Trp. No phenylthiohydantoin-coupled amino acid derivative was detected during cycles 1, 3, 11, and 15, which is consistent with the presence of cystine residues at these positions. The structure of trout ET, including the presence of four cystine residues, was confirmed by mass spectrometry. The observed molecular mass of the peptide was 2,507 ± 1 Da compared with a calculated mass of 2,506.0 Da for the proposed structure.
Chemical synthesis. A previous study
(13) has shown that air oxidation of fully reduced human ET-1 at a pH
>7 and at high dilution results in formation of an oxidized product
with disulfide bridges between
Cys1 and
Cys15 and between
Cys3 and
Cys11 (the pattern in naturally
occuring ET) in ~75% yield. Cyclization of synthetic linear trout ET
under the same experimental condition and subjecting the reaction
mixture to reversed-phase HPLC led to the elution profile shown in Fig.
3. The three major peaks in the
chromatogram (designated 1, 2, and 3) were analyzed by Edman
degradation and shown to have the same amino acid sequence as the
endogenous peptide. However, at a concentration of
~10
7 M, only
peak 2 produced a strong and sustained
contraction of isolated vascular rings of the trout epibranchial
artery. It is concluded, therefore, that peak
2 represents authenic trout ET, whereas
peaks 1 and
3 represent incorrectly folded
analogs. After a further chromatography on a Vydac
C18 column, the final yield of
pure trout ET was 3.1 mg. The identity of the synthetic peptide was
confirmed by mass spectrometry (observed molecular mass 2,506 ± 1 Da; calculated molecular mass 2,506.0 Da).
|
Myotropic activity. The responses of
trout vessels to trout ET and to rat or human ET-1 are shown in Figs.
4-6.
Synthetic trout ET produced concentration-dependent constrictions of
isolated vascular rings from EBA
(pD2 = 7.90 ± 0.06, n = 5), ACV
(pD2 = 8.57 ± 0.25, n = 4), and CMA (pD2 = 8.03 ± 0.04, n = 4) (pD2 =
log
EC50). Trout ET also produced
concentration-dependent constriction of the isolated rat abdominal
aorta (AO; pD2 = 8.86 ± 0.08, n = 7; Fig. 6). Rings from ACV were
responsive to significantly (P < 0.001) lower concentrations of trout ET than either CMA or EBA. The
EBA, ACV, and AO were more sensitive to mammalian ET-1 (pD2 for human ET-1: EBA = 9.12 ± 0.14; ACV = 9.90 ± 0.15; AO = 8.86 ± 0.08; all
P < 0.001). However, there was no
significant difference in the maximum tension produced by either
peptide in these vessels.
|
|
|
| |
DISCUSSION |
|---|
|
|
|---|
The primary structure of trout ET is compared with the structures of
three isoforms of human ET in Fig. 7. The
amino acid sequence of each isoform has been strongly conserved among
those mammalian species yet studied (human, pig, dog, rabbit, ox, and rat; reviewed in Refs. 23 and 26), with the only species-related sequence difference being the substitution
Ser4
Asn in mouse ET-2
(24). Trout ET contains three amino acid substitutions
(Ala4
Ser,
Thr5
Ser, and
Phe6
Trp) compared with
human ET-2 and an additional substitution (Leu7
Met) compared with
human ET-1. On this basis alone, however, it would be unreasonable to
claim that the trout peptide was the homolog of mammalian ET-2 rather
than ET-1 as the mammalian kidney synthesizes both ET-1 and ET-2 (25).
By way of comparison with a neuroendocrine peptide of comparable size,
trout gastrin-releasing peptide contains nine amino acid substitutions
and a four-residue deletion compared with human gastrin-releasing
peptide (7). The biosynthesis of the ET isoforms in mammals is atypical
in that posttranslational processing of preproendothelin at the site of
dibasic amino acid residues by prohormone convertases produces a
"big" ET of between 38 and 41 amino acids, depending on the species, that has low biological potency (11). Big ET is further processed by the highly selective ET-converting enzymes that exist in
several isoforms and cleaves at the
Trp21-Val22
bond in big ET-1 and ET-2 and at the
Trp21-Ile22
bond in ET-3 (25). The isolation of trout ET in a single 21-amino-acid form suggests that preproendothelin is probably processed in teleost fish by a similar pathway as in mammals. Our data do not exclude the
possibility that big ET is also present in trout tissues as the
antiserum used in this study for detection does not recognize big ET.
|
The origin of the ET isolated from the trout kidney is uncertain.
Whereas the material may represent, at least in part, peptide that is
synthesized in the kidney, it may also represent circulating ET that
has been internalized by the organ through receptor-mediated endocytosis. ET-like immunoreactivity has been measured in the plasma
of a range of teleost species (32), and receptor-mediated uptake of
circulating ET-1 by the rat kidney has been described (1). In mammals,
both paracrine and endocrine roles for ET in the regulation of renal
blood flow, glomerular filtration rate, and sodium and water excretion
have been proposed (26). However, continuous infusions of human ET-1 at
rates up to 30 ng · kg
1 · min
1
into unanesthetized trout had no effect on urine flow, osmolarity, and
electrolyte concentrations (21). The failure to detect ET-LI in
extracts of the other trout tissues examined was unexpected, especially
in light of the observation that extracts of brain, pituitary, liver,
kidney, stomach, and interrenal gland of the frog Rana
ridibunda contained detectable concentrations of ET-LI measured using the same antiserum (Y. Wang and J. M. Conlon,
unpublished observation). At this time, a plausible explanation for the
discrepancy between the two species is not available, and clearly
further studies are warranted to investigate the localization of ET in trout tissue by immunohistochemistry and/or in situ hybridization.
The actions of ET in mammals are mediated through interaction with two well-characterized receptors. The ETA receptor is selective for ET-1 and ET-2, whereas the ETB receptor exhibits similar affinities for all three isopeptides (27). Vasoconstrictor responses are effected by interaction with ETA receptors on vascular smooth muscle cells, and structure-activity studies have shown that either reduction or scrambling of the disulfide bonds leads to a greatly impaired ability to activate this receptor (12). It has been established that the Asp8, Glu10, and Phe14 residues in ET-1 are of critical importance in recognition by the ETA receptor (18). In contrast, vasodilatator responses are mediated through interactions with ETB receptors on endothelial cells, and it has been shown that linear ET analogs, such as [Ala1,3,11,15]ET-1 and certain NH2-terminally truncated fragments, are potent in the mediation of systemic vasodilation acting via the ETB receptor (2). These data have suggested that binding and activation of the ETA receptor requires both the highly ordered helical core region and the linear COOH-terminal domain of the ligand, whereas binding and activation of the ETB receptor needs only the latter structural feature. Our study has demonstrated that the by-products of the chemical synthesis of trout ET in which the pattern of the disulfide bonds did not correspond to that found in the endogenous peptides did not constrict isolated rings of trout vascular tissues. This observation, together with the fact that the Asp8, Glu10, and Phe14 residues and the COOH-terminal domain (residues 16-21) have been fully conserved, suggests that the vasoconstrictor actions of trout ET are mediated through interaction with a receptor that resembles the mammalian ETA receptor more closely than the ETB receptor. It is significant that replacement of Ser4, Ser5, and Leu6 in human ET-1, residues in trout ET that differ from the mammalian isoform by Ala, Ala, and Gly, respectively, resulted in analogs retaining vasoconstrictor activity (18).
Consistent with the results of a previous study investigating the effects of human ET-1 on trout vascular tissue (21), synthetic trout ET produced dose-dependent constriction of isolated rings of vascular tissue taken from vessels of the trout arterial and venous circulation. The sensitivity to trout ET of vascular rings from the anterior cardinal vein was significantly greater than the sensitivity of rings from either the EBA or the CMA. This observation is consistent with the earlier report that venous tissue was more sensitive than arterial tissue to human ET-1 (21) and is supported by our recent in vivo findings in the trout that are presented in a companion publication (6).
Perspectives
The study has demonstrated that the amino acid sequence of ET has been strongly conserved during the evolution of vertebrates. However, the isolation of only a single molecular form from trout tissues suggests that the putative gene duplications that have led to three ET isoforms in mammals may have taken place after the evolution of tetrapods. Consistent with this hypothesis, a related study has led to the purification from tissues of the frog Rana ridibunda of ET-1 with an amino acid sequence identical to human ET-1 and ET-3 that differs from human ET-3 by only one amino acid residue (Y. Wang, I. Remy-Jouet, C. Delarue, H. Vaudry, and J. M. Conlon, unpublished observation). The fact that the vasoconstrictor action of trout ET on trout vascular tissue is the same as the action of the mammalian ET isoforms on mammalian tissue is indicative of the fact that the role of ET in hemodynamic regulation has also been conserved across phylogenetic lines. The increased potency of human ET-1 relative to trout ET in constricting trout vessels was unexpected but may reflect the fact that human ET-1 is degraded more slowly than the native ET by peptidases in trout tissue. This result is not without precedent as, for example, salmon calcitonin is used therapeutically as a more potent and effective form of the hormone in the human.| |
ACKNOWLEDGEMENTS |
|---|
The authors thank Per F. Nielsen, Novo Nordisk, Bagsvaerd, Denmark for mass spectrometry measurements, Dr. D. D. Smith, Creighton Univ. Medical School for helpful advice regarding peptide synthesis, Dr. S. R. Bloom, Imperial College School of Medicine, London, UK and Dr. T. E. Adrian, Creighton Univ. Medical School for gifts of antiserum, and B. Briedert and the staff of the Richard Clay Bodine State Fish Hatchery, Mishawaka, IN for supplying the steelhead trout.
| |
FOOTNOTES |
|---|
This work was supported by Grants IBN-9806997 and IBN-9722306 from the National Science Foundation.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: J. M. Conlon, Dept. of Biomedical Sciences, Creighton Univ. Medical School, Omaha, NE 68178 (E-mail: jmconlon{at}creighton.edu).
Received 19 April 1999; accepted in final form 28 June 1999.
| |
REFERENCES |
|---|
|
|
|---|
1.
Anggard, E.,
S. Galton,
G. Rae,
R. Thomas,
L. McLoughlin,
G. deNucci,
and
J. R. Vane.
The fate of radioiodinated endothelin-1 and endothelin-3 in the rat.
J. Cardiovasc. Pharmacol.
3, Suppl. 5:
S46-S49,
1989.
2.
Bigaud, M.,
and
J. T. Pelton.
Discrimination between ETA and ETB receptor mediated effects of endothelin 1 and [Ala1,3,11,15]endothelin 1 by BQ123 in the anaesthetized rat.
Br. J. Pharmacol.
107:
912-918,
1992[Medline].
3.
Doi, Y,
and
S. Fujimoto.
Vasocontractions of the in-vitro toad aortas induced by endothelin-1 and sarafotoxin-S6b.
Anat. Rec.
235:
253-260,
1993[Medline].
4.
Evans, D. H.,
M. Gunderson,
and
C. Cegelis.
ETB-type receptors mediate endothelin-stimulated contraction in the aortic vascular smooth muscle of the spiny dogfish shark, Squalus acanthias.
J. Comp. Physiol. [A]
165:
659-664,
1996.
5.
Goniakowska-Witalinska, L.,
G. Zaccone,
S. Fasulo,
A. Mauceri,
A. Licata,
and
J. Youson.
Neuroendocrine cells in the gills of the bowfin Amia calva. An ultrastructural and immunocytochemical study.
Folia Histochem. Cytobiol.
33:
171-177,
1995[Medline].
6.
Hoagland, T. M., L. Weaver, Jr., J. M. Coulon, Y. Wang, and K. R. Olson. Effects of endothelin-1 and homologous trout endothelin on
cardiovascular function in rainbow trout. Am. J. Physiol.
(Regulatory Integrative Comp. Physiol.). In press.
7.
Jensen, J.,
and
J. M. Conlon.
Isolation and primary structure of gastrin-releasing peptide from a teleost fish, the trout (Oncorhynchus mykiss).
Peptides
13:
995-999,
1992[Medline].
8.
Inoue, A.,
M. Yanagisawa,
S. Kimura,
Y. Kasuya,
T. Miyauchi,
K. Goto,
and
T. Masaki.
The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes.
Proc. Natl. Acad. Sci. USA
86:
2863-2867,
1989
9.
Karne, S.,
C. K. Jayawickreme,
and
M. R. Lerner.
Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores.
J. Biol. Chem.
268:
19126-19133,
1993
10.
Kasuya, Y.,
H. Kobayashi,
and
H. Uemura.
Endothelin-like immunoreactivity in the nervous system of invertebrates and fish.
J. Cardiovasc. Pharmacol.
7, Suppl. 7:
S463-467,
1991.
11.
Kido, T.,
T. Sawamura,
and
T. Masaki.
The processing pathway of endothelin-1 production.
J. Cardiovasc. Pharmacol.
1, Suppl. 1:
S13-15,
1998.
12.
Kitazumi, K.,
T. Shiba,
K. Nishiki,
Y. Furukawa,
C. Takasaki,
and
K. Tasaka.
Structure activity relationship in vasoconstrictor effects of sarafotoxins and endothelin 1.
FEBS Lett.
260:
269-272,
1990[Medline].
13.
Kumagaye, S. I.,
H. Kuroda,
K. Nakajima,
T. X. Watanabe,
T. Kimura,
T. Masaki,
and
S. Sakakibara.
Synthesis and disulfide structure determination of porcine endothelin: an endothelium-derived vasoconstricting peptide.
Int. J. Pept. Protein Res.
32:
519-526,
1988[Medline].
14.
Kumar, C. S.,
V. Mwangi,
P. Nuthulaganti,
H. L. Wu,
M. Pullen,
K. Brun,
H. Aiyar,
R. A. Morris,
R. Naughton,
and
P. Nambi.
Cloning and characterization of a novel endothelin receptor from Xenopus heart.
J. Biol. Chem.
269:
13414-13420,
1994
15.
Kumar, C. S.,
P. Nuthulaganti,
M. Pullen,
and
P. Nambi.
Novel endothelin receptors in the follicular membranes of Xenopus laevis oocytes mediate calcium response by signal transduction through gap junctions.
Mol. Pharmacol.
44:
153-157,
1993[Abstract].
16.
Lecoin, L.,
T. Sakurai,
M. T. Ngo,
Y. Abe,
M. Yanagisawa,
and
N. M. LeDouarin.
Cloning and characterization of a novel endothelin receptor subtype in the avian class.
Proc. Natl. Acad. Sci. USA
95:
3034-3029,
1998.
17.
Lodhi, K. M.,
H. Sakaguchi,
S. Hirose,
and
H. Hagiwara.
Localization and characterization of a novel receptor for endothelin in the gills of the rainbow trout.
J. Biochem. (Tokyo)
118:
376-379,
1995
18.
Nakajima, K.,
S. Kubo,
S. I. Kumagaye,
H. Nishio,
M. Tsunemi,
T. Inui,
H. Kuroda,
N. Chino,
T. X. Watanabe,
T. Kimura,
and
S. Sakakibara.
Structure-activity relationship of endothelin: importance of charged groups.
Biochem. Biophys. Res. Commun.
163:
424-429,
1989[Medline].
19.
Nakamura, S.,
M. Naruse,
K. Naruse,
H. Demura,
and
H. Uemura.
Immunocytochemical localization of endothelin in cultured bovine endothelial cells.
Histochemistry
94:
475-477,
1990[Medline].
20.
Nambi, P.,
M. Pullen,
and
C. Kumar.
Identification of a novel endothelin receptor in Xenopus laevis liver.
Neuropeptides
26:
181-185,
1994[Medline].
21.
Olson, K. R.,
D. W. Duff,
A. P. Farrell,
J. Keen,
M. D. Kellogg,
D. Kullman,
and
J. Villa.
Cardiovascular effects of endothelin in trout.
Am. J. Physiol.
260 (Heart Circ. Physiol. 29):
H1214-H1223,
1991
22.
Poder, T. C.,
S. D. Silberberg,
and
D. Rampe.
Contraction of reptile, amphibian, and fish blood vessels by endothelin-1.
Can. J. Physiol. Pharmacol.
69:
215-217,
1991[Medline].
23.
Rubanyi, G. M.,
and
M. A. Polokoff.
Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology.
Pharmacol. Rev.
46:
325-415,
1994[Medline].
24.
Saida, K.,
Y. Mitsui,
and
N. Ishida.
A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family. Molecular cloning, expression, and biological activity.
J. Biol. Chem.
264:
14613-14616,
1989
25.
Shimada, K.,
M. Takahashi,
M. Ikeda,
and
K. Tanzawa.
Identification and characterization of two isoforms of an endothelin-converting enzyme-1.
FEBS Lett.
371:
140-144,
1995[Medline].
26.
Simonson, M. S.
Endothelins: multifunctional renal peptides.
Physiol. Rev.
73:
375-411,
1993
27.
Sokolovsky, M.
Endothelin receptor subtypes and their role in transmembrane signaling mechanisms.
Pharmacol. Ther.
68:
435-471,
1995[Medline].
28.
Suzuki, H.,
T. Yamamoto,
S. Kikuyama,
and
H. Uemura.
Distribution of endothelin 3-like immunoreactivity in gonadotrophs of the bullfrog (Rana catesbeiana) pituitary.
Gen. Comp. Endocrinol.
107:
12-22,
1997[Medline].
29.
Takasaki, C.,
Y. Itoh,
H. Onda,
and
M. Fujino.
Cloning and sequence analysis of a snake, Atractaspis engaddensis gene encoding sarafotoxin S6c.
Biochem. Biophys. Res. Commun.
189:
1527-1533,
1992[Medline]
30.
Takasaki, C.,
N. Tamiya,
A. Bdolah,
Z. Wollberg,
and
E. Kochva.
Sarafotoxin S6: several isotoxins from Atractaspis engaddensis (burrowing asp) venom that affect the heart.
Toxicon
26:
543-548,
1988[Medline].
31.
Takahashi, K.,
K. Suda,
H.-C. Lam,
M. A. Ghatei,
and
S. R. Bloom.
Endothelin-like immunoreactivity in rat models of diabetes mellitus.
J. Endocrinol.
130:
123-127,
1991[Abstract].
32.
Uemura, H.,
M. Naruse,
K. Naruse,
T. Hirohama,
H. Demura,
and
Y. Kasuya.
Immunoreactive endothelin in plasma of non-mammalian vertebrates.
J. Cardiovasc. Pharmacol.
17, Suppl. 7:
S414-S416,
1991
33.
Waugh, D.,
K. E. Groff,
B. Platzack,
J. H. Youson,
K. R. Olson,
and
J. M. Conlon.
Isolation, localization, and cardiovascular activity of tachykinins from the stomach of the bowfin, Amia calva.
Am. J. Physiol.
269 (Regulatory Integrative Comp. Physiol. 38):
R565-R571,
1995
34.
Zaccone, G.,
A. Mauceri,
S. Fasulo,
L. Ainis,
P. Lo Cascio,
and
M. B. Ricca.
Localization of immunoreactive endothelin in the neuroendocrine cells of fish gill.
Neuropeptides
30:
53-57,
1996[Medline].
35.
Zigdon-Arad, T.,
A. Bdolah,
E. Kochva,
and
Z. Wollberg.
Activity of sarafotoxin/endothelin peptides in the heart and brain of lower vertebrates.
Toxicon
30:
439-448,
1992[Medline].
This article has been cited by other articles:
![]() |
D. H. Evans Teleost fish osmoregulation: what have we learned since August Krogh, Homer Smith, and Ancel Keys Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2008; 295(2): R704 - R713. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Vierimaa, J. Ronkainen, H. Ruskoaho, and O. Vuolteenaho Synergistic activation of salmon cardiac function by endothelin and beta-adrenergic stimulation Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1360 - H1370. [Abstract] [Full Text] [PDF] |
||||
![]() |
K.-O. Stenslokken, L. Sundin, and G. E. Nilsson Endothelin receptors in teleost fishes: cardiovascular effects and branchial distribution Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R852 - R860. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Evans, P. M. Piermarini, and K. P. Choe The Multifunctional Fish Gill: Dominant Site of Gas Exchange, Osmoregulation, Acid-Base Regulation, and Excretion of Nitrogenous Waste Physiol Rev, January 1, 2005; 85(1): 97 - 177. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. H. Evans, R. E. Rose, J. M. Roeser, and J. D. Stidham NaCl transport across the opercular epithelium of Fundulus heteroclitus is inhibited by an endothelin to NO, superoxide, and prostanoid signaling axis Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2004; 286(3): R560 - R568. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Minerick, H.-C. Chang, T. M. Hoagland, and K. R. Olson Dynamic synchronization analysis of venous pressure-driven cardiac output in rainbow trout Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2003; 285(4): R889 - R896. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Olson, D. W. Kinney, R. A. Dombkowski, and D. W. Duff Transvascular and intravascular fluid transport in the rainbow trout: revisiting Starling's forces, the secondary circulation and interstitial compliance J. Exp. Biol., February 1, 2003; 206(3): 457 - 467. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Platzack, Y. Wang, D. Crossley, V. Lance, J. W. Hicks, and J. M. Conlon Characterization and cardiovascular actions of endothelin-1 and endothelin-3 from the American alligator Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2002; 282(2): R594 - R602. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Hoagland, L. Weaver Jr., J. M. Conlon, Y. Wang, and K. R. Olson Effects of endothelin-1 and homologous trout endothelin on cardiovascular function in rainbow trout Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2000; 278(2): R460 - R468. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |